TOP NEWS and HEADLINES in January
- Researchers Discover Inner Ear Cells Resistant to Notch Signaling
- Sensaphonics Founder Earns AuD, Joins AAA Foundation Board
- Chemotherapy Can Cause Hearing Loss
- Sonomax Inks $2 Million Deal with 3M
- Cathy Jones Elected President of Better Hearing Institute
- A Hearing Protection Pill?
- Children with Cochlear Implants Perceive Improved Quality of Life, Study Shows
- New Generation Golf Clubs Linked to Hearing Loss
- Mike Orscheln Named New Phonak US Chief
- Hearing Aid Specialist Vocational School Licensed in Texas
- Obituary: Judith Gravel, PhD
- China Summit: A “Milestone For Audiology”
Listen to HR’s Science and Technology Thursday Podcast for the field’s most exciting research at www.hearingreview.com/sciencetech.
- Proposed ADA Regulations Withdrawn from OMB Review. The Department of Justice on January 21 notified the Office of Management and Budget (OMB) that the Department has withdrawn its draft final rules to amend the Department’s regulations implementing title II and title III from the OMB review process. The action was taken in response to a memorandum from the President’s chief of staff directing the executive branch agencies to defer publication of any new regulations until the rules are reviewed and approved by officials appointed by the president. No final action will be taken by the department in regard to these rules until the incoming officials have had the opportunity to review the rule-making record. Incoming officials will have the full range of rule-making options available to them under the Administrative Procedure Act. Withdrawal of the draft final rules does not affect existing ADA regulations. Title II and title III entities must continue to follow the Department’s existing ADA regulations, including the ADA Standards for Accessible Design. Source: Department of Justice
- EarQ Debuts Management Programs. EarQ Group, Syracuse, NY, introduces its Financial Freedom Program, giving private practices access to business services that may be difficult and costly for many small companies to offer. It includes retirement planning, health insurance, human resources support, and patient information management. An EarQ Group membership is required to sign up for the program. Members can choose some or all of the services, which can be provided at no cost. Source: EarQ Group
- Chemotherapy Can Cause Hearing Loss. London—A pharmaceutical company is joining the Center for Hearing and Deafness at the State University of New York in an investigation of hearing loss as a side effect associated with the chemotherapy medication cisplatin. The chemotherapy damages the cochlear hair cells in the inner ear that vibrate in response to sound waves. While the link between cisplatin treatment and hearing loss is well known, the new study aims to be the first effort to identify the direct correlation. According to Kristy Gilmer Knight, a pediatric audiologist at Oregon Health & Science University’s (OHSU) Doernbecher Children’s Hospital, the problem is more widespread and pressing than most people realize. OHSU researchers tested the hearing in 67 patients, ages 8 months to 23 years following their chemotherapy; 61 of them were found to have hearing loss.
- Typically, the resulting hearing loss from cisplatin chemotherapy is high-frequency hearing loss, making the hearing impairment less obvious. Children are most at risk, but the precise risk of hearing loss from cisplatin is yet to be determined. Source: Audiology Online; Royal National Institute for Deaf People
Want the inside scoop?
Every week The Hearing Review sends out THE INSIDER, a weekly FREE e-newsletter devoted to the top hearing-related news, research, product introductions, fitting topics, and marketing research stories that are influencing your business or practice, as well as the industry at large. [register]Sign up for your free subscription[/register].